New data from Eli Lilly shows that their weight loss drug Zepbound helped patients lose more weight on average than Novo Nordisk’s Wegovy. Patients on Zepbound lost 20.2% of their body weight in 72 weeks, compared to 13.7% for those on Wegovy. While Wegovy currently has a larger market share, this new data could sway payers in favor of Eli Lilly in the future. This ongoing battle in the Glp-1 market may shift in favor of the Indianapolis-based pharma company if the promising results continue.
Source link
Health Information Management